RVNC - Revance Therapeutics GAAP EPS of -$0.94 beats by $0.02 revenue of $25.26M beats by $1.39M May, 10 2022 04:15 PM Revance Therapeutics Inc. Revance Therapeutics press release (NASDAQ:RVNC): Q1 GAAP EPS of -$0.94 beats by $0.02. Revenue of $25.26M (+89.9% Y/Y) beats by $1.39M. For further details see: Revance Therapeutics GAAP EPS of -$0.94 beats by $0.02, revenue of $25.26M beats by $1.39M